Skip to content

Side by side

AOD-9604 vs Tirzepatide

Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.

AOD-9604 and Tirzepatide compared on what BioAlmanac records.
 AOD-9604Tirzepatide
What it isA growth hormone fragment developed as an obesity drug. It completed human trials, and they did not show weight loss beyond placebo.A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.
EvidenceHow much human evidence exists, not how well it works.Early human trialsApproved
Regulatory statusReviewed 2026-08-12Not currently approved for human use in the United States. Development as an obesity treatment was discontinued after trials failed to show benefit. Sold as a research chemical and — in some markets — marketed in ways that do not reflect that outcome.Approved by the FDA as a prescription medicine for type 2 diabetes and for chronic weight management. Material sold as a research chemical is not the approved product and is not legal to sell for human use.
RoutesSubcutaneousSubcutaneous
Half-life0.5 hours120 hours
Cheapest per mgVials only, read from vendors' own listings and dated on the price index.$2.60/mg$1.00/mg
Median per mg$8.90/mg$3.17/mg
Vendors with a price4033
Storage once mixedRefrigerated at 2–8 °C. Do not freeze once mixed.Refrigerated at 2–8 °C. Do not freeze. Discard if cloudy or discoloured.

Compare two other compounds · The full price index

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.